drugset / Trial / NCT03533751
Efficacy, Safety, and Pharmacokinetic Profile of Etokimab (ANB020) in Adult Participants With Moderate-to-Severe Atopic Dermatitis
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This study is designed to evaluate the efficacy, safety, and pharmacokinetic (PK) profiles of multiple doses of etokimab in adult participants with atopic dermatitis (AD).
Timeline
- Start
- 2018-06-19
- Primary completion
- 2019-12-03
- Completion
- 2019-12-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Etokimab | Monoclonal antibody | 20 mg | Subcutaneous |
| Subject | Etokimab | Monoclonal antibody | 150 mg | Subcutaneous |
| Subject | Etokimab | Monoclonal antibody | 300 mg | Subcutaneous |